Drug
Obrixtamig Parenteral 1
Obrixtamig Parenteral 1: highest development phase Phase 1, developed by Boehringer Ingelheim. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Boehringer Ingelheim
Trials
| Drug | Phase | Indication |
|---|---|---|
| Obrixtamig - parenteral 1 NCT04429087 | Phase 1 | Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3 |
Latest
No recent events.
Follow Obrixtamig Parenteral 1 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.